aflibercept-ayyh (Pavblu) vs Tarcocimab tedromer

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

Tarcocimab tedromer

Developed by Kodiak Sciences Inc.

Phase 3 in Age-Related Macular Degenerationmonoclonal antibody-biopolymer conjugate
Partial signal

NCT06556368 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)

Result source: NCT04964089

Results for Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. aflibercept-ayyh (Pavblu): 4 of 4 rows · Tarcocimab tedromer: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricaflibercept-ayyh (Pavblu)Tarcocimab tedromer
Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.3%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14.1%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
covid-19 12.3%
neovascular age-related macular degeneration - fellow eye 8%
vitreous floaters - study eye 7.6%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Tarcocimab tedromer

BCVA Change Letters 2.5 vs 4.6 Aflibercept ETDRS Letters @ 44wk
absolute change · ETDRS Letters
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 5 Letters 36.2% (n=276) vs 34.2% (n=281) Aflibercept @ 2wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 2
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 100 Participants as posted
BCVA Gain 5 Letters 39.9% (n=276) vs 45.9% (n=281) Aflibercept @ 4wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 4
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 110 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 53.7% (n=281) Aflibercept @ 8wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 8
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 44.9% (n=276) vs 52.7% (n=281) Aflibercept @ 12wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 12
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 124 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 50.9% (n=281) Aflibercept @ 16wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 16
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 43.8% (n=276) vs 57.3% (n=281) Aflibercept @ 20wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 20
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 121 Participants as posted
BCVA Gain 5 Letters 47.1% (n=276) vs 55.5% (n=281) Aflibercept @ 24wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 24
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 130 Participants as posted
BCVA Gain 5 Letters 44.2% (n=276) vs 54.8% (n=281) Aflibercept @ 28wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 28
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 122 Participants as posted
BCVA Gain 5 Letters 47.8% (n=276) vs 59.8% (n=281) Aflibercept @ 32wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 32
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 132 Participants as posted
BCVA Gain 5 Letters 43.5% (n=276) vs 56.2% (n=281) Aflibercept @ 36wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 36
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 120 Participants as posted
BCVA Gain 5 Letters 42% (n=276) vs 55.5% (n=281) Aflibercept @ 40wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 40
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 116 Participants as posted

+ 68 further endpoints in the CSV export.

Wet Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Wet Age-Related Macular Degeneration pipeline

aflibercept-ayyh (Pavblu)

Marketed by Amgen

Approved in Wet Age-Related Macular Degenerationfusion protein
Reliable signal

NCT04270747 · Phase 3 · completed

This was a randomized, double-masked, active-controlled trial with 576 participants, comparing ABP 938 with aflibercept. The clinical primary endpoint was met for similarity: the 90% confidence interval for the treatment difference in Week 8 visual-acuity change (-1.1 to 1.3 ETDRS letters) was entirely within the prespecified -3 to 3 letter margin.

Reported efficacy

Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): Mean Change From Baseline in BCVA at Week 8 (Baseline and Week 8): ABP 938 6.4 Letters (Standard Deviation 8.18) vs Aflibercept 6.5 Letters (Standard Deviation 8.97) (met)

Result source: NCT04270747

Tarcocimab tedromer

Developed by Kodiak Sciences Inc.

Phase 3 in Wet Age-Related Macular Degenerationmonoclonal antibody-biopolymer conjugate
Partial signal

NCT06556368 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)

Result source: NCT04964089

Results for Wet Age-Related Macular Degeneration

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. aflibercept-ayyh (Pavblu): 4 of 4 rows · Tarcocimab tedromer: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricaflibercept-ayyh (Pavblu)Tarcocimab tedromer
Dropout rate
5.2%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
8.3%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Discontinued due to AEs
0.3%ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
—Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
—Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.9%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Serious AEs
—ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 2 more results
8.1%Post Week 16: ABP 938 / ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
2.1%Through Week 16: ABP 938
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
14.1%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
Most frequent reported AEs
neovascular age-related macular degeneration 5.9%
conjunctival haemorrhage 1.5%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 1 more result
conjunctival haemorrhage 4.2%
neovascular age-related macular degeneration 2.1%
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
covid-19 12.3%
neovascular age-related macular degeneration - fellow eye 8%
vitreous floaters - study eye 7.6%
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

aflibercept-ayyh (Pavblu)

BCVA Change Letters 6.4 vs 6.5 Aflibercept Letters @ 8wk
absolute change · Letters
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 8 more results
5 vs 5.4 Aflibercept Letters @ 4wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.5 vs 7.6 Aflibercept Letters @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
6.8 vs 7.5 Aflibercept Letters @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 7.1 Aflibercept Letters @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.1 vs 8.7 Aflibercept Letters @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.3 vs 8.1 Aflibercept Letters @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.2 vs 8.7 Aflibercept Letters @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
7.6 vs 9.4 Aflibercept Letters @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Maintained Vision 95.6% (n=251) vs 97.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 10 Letters 29.4% (n=279) vs 32.7% (n=281) Aflibercept @ 8wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 15 Letters 24.3% (n=251) vs 29.6% (n=125) Aflibercept @ 52wk
responder rate · % of participants
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CNV Area Change Mm2 -4.962 vs -5.479 Aflibercept mm @ 8wk
absolute change · mm
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 3 more results
-4.089 vs -5.174 Aflibercept mm @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-4.323 vs -5.308 Aflibercept mm @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-6.276 vs -7.28 Aflibercept mm @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
CST Change Microns -136.5 vs -143.1 Aflibercept m @ 4wk
absolute change · m
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
show 7 more results
-145.9 vs -146.3 Aflibercept m @ 8wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-125.2 vs -127.3 Aflibercept m @ 16wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-130.8 vs -131.7 Aflibercept m @ 24wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-133.2 vs -134.1 Aflibercept m @ 32wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -135.6 Aflibercept m @ 40wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-132.3 vs -141.1 Aflibercept m @ 48wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
-157.1 vs -159.1 Aflibercept m @ 52wk
NCT04270747 · Phase 3 · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3

Tarcocimab tedromer

BCVA Change Letters 2.5 vs 4.6 Aflibercept ETDRS Letters @ 44wk
absolute change · ETDRS Letters
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3
BCVA Gain 5 Letters 36.2% (n=276) vs 34.2% (n=281) Aflibercept @ 2wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 2
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 100 Participants as posted
BCVA Gain 5 Letters 39.9% (n=276) vs 45.9% (n=281) Aflibercept @ 4wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 4
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 110 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 53.7% (n=281) Aflibercept @ 8wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 8
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 44.9% (n=276) vs 52.7% (n=281) Aflibercept @ 12wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 12
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 124 Participants as posted
BCVA Gain 5 Letters 43.1% (n=276) vs 50.9% (n=281) Aflibercept @ 16wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 16
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 119 Participants as posted
BCVA Gain 5 Letters 43.8% (n=276) vs 57.3% (n=281) Aflibercept @ 20wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 20
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 121 Participants as posted
BCVA Gain 5 Letters 47.1% (n=276) vs 55.5% (n=281) Aflibercept @ 24wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 24
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 130 Participants as posted
BCVA Gain 5 Letters 44.2% (n=276) vs 54.8% (n=281) Aflibercept @ 28wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 28
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 122 Participants as posted
BCVA Gain 5 Letters 47.8% (n=276) vs 59.8% (n=281) Aflibercept @ 32wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 32
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 132 Participants as posted
BCVA Gain 5 Letters 43.5% (n=276) vs 56.2% (n=281) Aflibercept @ 36wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 36
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 120 Participants as posted
BCVA Gain 5 Letters 42% (n=276) vs 55.5% (n=281) Aflibercept @ 40wk
event count · % of participants
Gain ≥5 ETDRS Letters at Week 40
NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 · converted to % from 116 Participants as posted

+ 68 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aflibercept-ayyh (Pavblu)'s landscape · Tarcocimab tedromer's landscape